Bifunctional Compounds Degrade KAT6A via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors for KAT6A may not effectively target KAT6A in a selective manner, limiting their therapeutic potential in cancers dependent on KAT6A for growth, proliferation, or survival.
Innovation Solution
Development of bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, which specifically degrade KAT6A through targeted protein degradation (TPD) approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to target KAT6A, then inhibition of KAT6A activity is achieved, but selectivity and therapeutic potential are limited
Solution Approach 1:
The compound is divided into two functional segments: a KAT6A binding moiety (PTM) that provides selective target recognition and an E3 ubiquitin ligase binding moiety (ULM) that recruits the degradation machinery. This segmentation allows each part to perform its specialized function, achieving both selectivity and therapeutic efficacy.
Solution Approach 2:
The compound acts as an intermediary molecule that bridges KAT6A and the Cereblon E3 ubiquitin ligase. By containing both binding moieties, it mediates the interaction between the target protein and the degradation system, enabling selective targeted protein degradation.
2Reliability
If traditional small molecule inhibitors are used, then KAT6A activity is inhibited, but the therapeutic window is limited
Solution Approach 1:
The invention changes the mechanism of action parameter from simple inhibition to targeted protein degradation. This parameter change results in more complete and sustained target reduction, expanding the therapeutic window by achieving greater efficacy at lower doses.
3Reliability
If bifunctional compounds are used to degrade KAT6A, then selectivity and potency are enhanced, but molecular complexity increases
Solution Approach 1:
Two separate functional moieties (KAT6A binding moiety and E3 ligase binding moiety) are merged into a single bifunctional compound. This combining approach maintains the simplicity of small molecule chemistry while achieving the enhanced selectivity and potency of targeted degradation.
Solution Approach 2:
The bifunctional compound structure provides a universal platform where different PTM and ULM modules can be combined. This multi-functionality allows the same general structure to target different proteins by swapping modules, reducing overall complexity through standardization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bifunctional compounds effectively modulate KAT6A by degrading it, potentially enhancing the therapeutic window in cancers reliant on KAT6A, thereby offering a more selective and potent approach compared to traditional small molecule inhibitors.
Implementation Method 1
bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, which specifically degrade KAT6A through targeted protein degradation (TPD) approaches
Data Source
AI summary
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.